Linlang Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Linlang Guo has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Qian Chen
Department of Pathology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China
2 shared publications- Chao Zhang
Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
1 shared publication - Dayong Yang
Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai, China
1 shared publication Haipeng Tang
Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China
1 shared publicationHexi Zhu
Department of General Surgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510282, PR China
1 shared publicationJialin Zeng
Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, P. R. China
1 shared publication
Latest Publications
- Open Access
- 4 December 2025
- Published by Elsevier in SLAS Technology
- Vol. 36, 100379
Viral peptides remodel the tumor immune microenvironment of cold tumors with RNA-seq insights
- 4 December 2025
- Published by Elsevier in SLAS Technology
- Vol. 36, 100379
Open AccessViral peptides remodel the tumor immune microenvironment of cold tumors with RNA-seq insights
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
A DNA Nanomachine Modulates the Stemness-Associated Signaling Pathways for Overcoming Chemoresistance by Temporally Programming Drug Release
Chemoresistance is a primary cause of cancer treatment failure, due to the lack of specific regulatory strategies arising from unclear mechanisms. Here, we uncover the pivotal role of the PRMT1/SOX2 axis in regulating cancer stemness, a key factor contributing to cancer chemoresistance. In light of this, we construct a DNA nanomachine (DNM) to overcome chemoresistance by reversing cancer stemness. This DNM is constructed using a programmable DNA origami framework, incorporating CD44-targeting aptamers and glutathione (GSH)-responsive stemness inhibitors (DCLX069) as functional components. The DNM exhibits a specific affinity toward CD44-overexpressing tumor cells, enabling the effective delivery of the loaded cisplatin (CDDP) to the tumor cells. Upon entering the tumor cells, DCLX069 is rapidly released from the DNM due to high intracellular GSH levels, leading to swift regulation of the PRMT1/SOX2 axis. In contrast, CDDP exhibits a gradual enzymatic release profile. This temporally programmed release enables the reversal of cancer stemness before chemotherapy initiation, resulting in a substantial improvement in CDDP chemosensitivity and a significant increase in the median survival of tumor-bearing mice from 27 to over 56 d with DNM assistance. This study highlights the promising potential of this DNA nanotechnology-empowered therapy in addressing chemoresistance in malignant tumors.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Research
- Vol. 8
Open AccessA DNA Nanomachine Modulates the Stemness-Associated Signaling Pathways for Overcoming Chemoresistance by Temporally Programming Drug Release
Chemoresistance is a primary cause of cancer treatment failure, due to the lack of specific regulatory strategies arising from unclear mechanisms. Here, we uncover the pivotal role of the PRMT1/SOX2 axis in regulating cancer stemness, a key factor contributing to cancer chemoresistance. In light of this, we construct a DNA nanomachine (DNM) to overcome chemoresistance by reversing cancer stemness. This DNM is constructed using a programmable DNA origami framework, incorporating CD44-targeting aptamers and glutathione (GSH)-responsive stemness inhibitors (DCLX069) as functional components. The DNM exhibits a specific affinity toward CD44-overexpressing tumor cells, enabling the effective delivery of the loaded cisplatin (CDDP) to the tumor cells. Upon entering the tumor cells, DCLX069 is rapidly released from the DNM due to high intracellular GSH levels, leading to swift regulation of the PRMT1/SOX2 axis. In contrast, CDDP exhibits a gradual enzymatic release profile. This temporally programmed release enables the reversal of cancer stemness before chemotherapy initiation, resulting in a substantial improvement in CDDP chemosensitivity and a significant increase in the median survival of tumor-bearing mice from 27 to over 56 d with DNM assistance. This study highlights the promising potential of this DNA nanotechnology-empowered therapy in addressing chemoresistance in malignant tumors.